Therapeutic Strategies that Target Epigenetic, Paracrine and Signalling Control of Skeletal Muscle Regeneration
Skeletal muscle is highly efficient at self-repair following injury via a complex interplay of muscle and nonmuscle
cellular components, soluble growth factors, and the extracellular matrix. Under certain circumstances, such as after
extensive acute tissue injury, prolonged periods of muscle disuse, and in some diseases, the regenerative capacity of
muscle can be overwhelmed or impaired. Predictive muscle break down can also occur (e.g., in age-related loss of muscle
mass and function, and post-operatively when procedures involve direct muscle damage, denervation or loss of blood supply),
and strategies that facilitate muscle regeneration and reduce recovery time or the effects of ageing would be highly
beneficial. Thus, there is a need for therapeutic approaches that promote muscle regeneration after injury, and/or to preemptively
protect muscles from damage. Recent research has culminated in a range of patents that focus on the therapeutic
enhancement of skeletal muscle regeneration and/or protection of existing muscle mass. This paper reviews recent research
developments and therapeutically-based patents and patent applications that target epigenetic, paracrine, and signalling
mechanisms underlying the normal regeneration process.
Keywords: Ageing, epigenetic, growth factor, muscular dystrophy, myogenesis, regeneration, skeletal muscle, signal transduction, MYOGENIC PROCESSES, myoblast proliferation.
Rights & PermissionsPrintExport